Search results
3 days ago · 01:48 - Source: CNN. CNN —. On Monday, a panel of independent advisers to the US Food and Drug Administration voted to endorse Eli Lilly’s drug donanemab, a monoclonal antibody designed to ...
4 days ago · Last July, a study published in the Journal of the American Medical Association reported Eli Lilly's Alzheimer's drug slowed decline by 35% compared with a placebo group based on a measure of ...
May 3, 2023 · A committee of independent advisers to the F.D.A. voted unanimously that the benefits outweigh the risks of donanemab, the newest experimental drug made by Eli Lilly for Alzheimer’s disease.
INDIANAPOLIS, May 3, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today positive results of the TRAILBLAZER-ALZ 2 Phase 3 study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer's disease.
4 days ago · A panel of independent advisors to the Food and Drug Administration on Monday recommended Eli Lilly ’s Alzheimer’s drug donanemab, paving the way for the treatment to receive full approval in ...
May 4, 2023 · An experimental Alzheimer’s medication slowed declines in patients’ ability to think clearly and perform daily tasks by more than a third in a large clinical trial, drugmaker Eli Lilly said...
May 3, 2023 · I n a May 3 press release, Eli Lilly announced encouraging results from its latest study of its Alzheimer’s drug candidate, donanemab. In the Phase 3 study, which included more than 1,000 people...
